Bridgebio Pharma Inc

24. Sept. 2026, 22:01 UTC

BridgeBio Pharma Inc's shares rose in after-market trading, despite remaining significantly below their 20-day moving average and near the lower end of their one-month range.

23. Sept. 2026, 20:03 UTC

BridgeBio Pharma's shares fell despite positive study results showing Acoramidis significantly reduces clinical worsening risk in ATTR-CM compared to Tafamidis.

22. Sept. 2026, 23:21 UTC

BridgeBio Pharma Inc has advanced in after-market trading, reaching its highest cumulative return since Tuesday's close, following a significant increase from a recent low.

18. Sept. 2026, 19:55 UTC

BridgeBio Pharma Inc shares fell amid potential further liquidation by KKR, currently remaining below the 20-day moving average and near the lower end of its one-month range.

17. Sept. 2026, 19:16 UTC

BridgeBio Pharma Inc shares fell sharply, retracing from an earlier peak and trading significantly below its 20-day moving average.

16. Sept. 2026, 23:01 UTC

BridgeBio Pharma Inc is trading modestly lower in after-market hours, positioned below its 20-day moving average and near the lower end of its one-month range.

15. Sept. 2026, 20:01 UTC

BridgeBio Pharma Inc shares are trading lower as U.S. bond yields rise, with the recent 20-Year Bond Auction yield exceeding expectations and raising investor concerns.

14. Sept. 2026, 20:07 UTC

BridgeBio Pharma Inc shares are lower amid a declining market trend. Discussions on acoramidis' clinical results have not clarified its overall disease management impact.

11. Sept. 2026, 19:56 UTC

BBIO lower as JPMorgan cuts price target to $23.00.

10. Sept. 2026, 23:01 UTC

BridgeBio Pharma Inc shares are higher in after-market trading, recovering sharply despite being below its 20-day moving average and near a one-month low.

9. Sept. 2026, 22:46 UTC

BridgeBio Pharma Inc shares are higher in after-market trading, despite no specific news. Broader market pressure persists from rising crude oil prices above $100.

2. Sept. 2026, 19:36 UTC

BridgeBio Pharma will present new infigratinib data at a pediatric endocrinology meeting in September. HC Wainwright maintains a Buy rating and $120 price target.

1. Sept. 2026, 23:16 UTC

BridgeBio Pharma shares are lower in after-market hours following a $500 million mixed securities shelf filing, raising concerns about potential dilution.

28. Aug. 2026, 20:08 UTC

BridgeBio Pharma Inc's shares are lower today, continuing a downward trend despite positive social media discussions regarding its treatment, Attruby, based on WF's analysis.

20. Aug. 2026, 19:46 UTC

Shares lower amid broader biotechnology sector decline.

19. Aug. 2026, 23:01 UTC

BridgeBio Pharma Inc shares are higher in after-market trading, recovering from earlier lows. Broader market gains in cryptocurrencies may reflect a shift in investor sentiment.

18. Aug. 2026, 20:06 UTC

BridgeBio Pharma Inc shares are higher, supported by social media discussions on Attruby's potential market share and anticipation for upcoming clinical data.

14. Aug. 2026, 20:06 UTC

BridgeBio Pharma's shares decline as it announces a secondary offering of 5 million shares priced at $78.00, managed by KKR and others.

13. Aug. 2026, 23:01 UTC

BridgeBio Pharma Inc shares are lower in after-market hours following the announcement of a secondary public offering of 5,000,000 shares on behalf of KKR.

12. Aug. 2026, 19:51 UTC

BridgeBio Pharma Inc shares are lower today despite multiple analyst price target upgrades. Management noted waning physician enthusiasm for a combination therapy.

11. Aug. 2026, 22:36 UTC

BridgeBio Pharma Inc. shares are lower in after-market trading, fluctuating within a narrow range with no specific news identified.

10. Aug. 2026, 23:21 UTC

BridgeBio Pharma Inc. reported second-quarter revenues of $243.7 million, exceeding expectations. Shares are higher in after-market trading amid positive reception for Attruby.

7. Aug. 2026, 20:03 UTC

BridgeBio Pharma Inc is gaining traction amid strong biotech sector performance. Cantor Fitzgerald lists it as a top pick ahead of its earnings report.

6. Aug. 2026, 19:16 UTC

BridgeBio Pharma Inc's shares are higher, reflecting a modest gain since Wednesday's close amid mixed market sentiment ahead of the non-farm payrolls report.

5. Aug. 2026, 19:16 UTC

BridgeBio Pharma Inc. shares are lower today, with no specific news identified. The stock retraced from earlier gains, reflecting broader market trends.

4. Aug. 2026, 19:36 UTC

BridgeBio Pharma Inc shares rise as Piper Sandler sets a price target of $111 following the LGMD Scientific Summit. Biotech sector momentum supports the increase.

3. Aug. 2026, 20:06 UTC

BridgeBio Pharma Inc shares are lower today, breaking from a recent trend of higher daily closes. No specific news was identified to explain the decline.

31. Juli 2026, 19:56 UTC

BBIO shares decline, continuing a three-day trend amid sector weakness.

30. Juli 2026, 20:21 UTC

BridgeBio Pharma Inc shares rose in after-market trading, reflecting positive market sentiment. The stock's performance aligns with an upward trend in the Russell 2000 Index.

29. Juli 2026, 17:36 UTC

BridgeBio Pharma Inc shares are lower today, reaching a pre-market low before a slight recovery. No specific news was identified to explain the decline.